UAB30, A Novel Rexinoid Agonist, Decreases Stemness In Group 3 Medulloblastoma Human Cell Line Xenografts

PURPOSE: In spite of advances in therapy for some subtypes, group 3 medulloblastoma continues to portend a poor prognosis. A subpopulation of medulloblastoma cells expressing the cell surface marker CD133 have been posited as possible stem cell like cancer cells (SCLCC), a potential source of drug r...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Transl Oncol
Autors principals: Williams, Adele P., Garner, Evan F., Stafman, Laura L., Aye, Jamie M., Quinn, Colin H., Marayati, Raoud, Stewart, Jerry E., Atigadda, Venkatram R., Mroczek-Musulman, Elizabeth, Moore, Blake P., Beierle, Elizabeth A., Friedman, Gregory K.
Format: Artigo
Idioma:Inglês
Publicat: Neoplasia Press 2019
Matèries:
Original article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6664160/
https://ncbi.nlm.nih.gov/pubmed/31362265
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.tranon.2019.07.003
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars